Ghent University Academic Bibliography

Advanced

Incorporating PARP-inhibitors into clinical routine : a tailored treatment strategy to tackle ovarian cancer

Emiel De Jaeghere, Katrien Vandecasteele UGent, Kathleen Claes UGent, Amin Makar UGent, PHILIPPE TUMMERS, Veronique Cocquyt UGent and Hannelore Denys UGent (2017) ACTA CLINICA BELGICA. 72(1). p.6-11
abstract
DNA repair mechanisms play a key role in oncogenesis and cancer progression in women with BRCA mutation-positive (BRCAm) ovarian cancer (OC). The BRCA1/2 and poly(ADP-ribose) polymerase (PARP) proteins are considered the foremost mediators among the various components of double-strand and single-strand repair, respectively. A series of new therapeutic drugs that target PARP have been developed for BRCAm OC. This class of agents provokes tumour-specific cytotoxicity with minimal side effects by inducing synthetic lethality, of which they are the first clinical example. The European Medicines Agency granted accelerated licensing approval for the first-in-class-drug that inhibits PARP, olaparib (Lynparza, AstraZeneca). Olaparib can be used as a monotherapeutic maintenance treatment in patients with platinum-sensitive relapsed (germline and/or somatic) BRCAm high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer responsive to platinum-based chemotherapy. Seen in light of these recent events, this review article will focus on (a) how PARP-inhibitors exploit cancer-specific defects in the homologous recombination repair apparatus and (b) how BRCA testing is implemented in routine clinical care.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
PARP-inhibitors, Olaparib, BRCA, Ovarian cancer, Targeted therapy, RIBOSE POLYMERASE INHIBITORS, OLAPARIB MAINTENANCE THERAPY, POLY(ADP-RIBOSE) POLYMERASE, HOMOLOGOUS RECOMBINATION, SOMATIC MUTATIONS, PHASE-2 TRIAL, BRCA STATUS, REPAIR, TUMORS, CELLS
journal title
ACTA CLINICA BELGICA
Acta Clin. Belg.
volume
72
issue
1
pages
6 - 11
Web of Science type
Review
Web of Science id
000395099100003
ISSN
1784-3286
DOI
10.1080/17843286.2016.1188455
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
7243968
handle
http://hdl.handle.net/1854/LU-7243968
date created
2016-06-06 10:50:22
date last changed
2017-07-06 11:54:41
@article{7243968,
  abstract     = {DNA repair mechanisms play a key role in oncogenesis and cancer progression in women with BRCA mutation-positive (BRCAm) ovarian cancer (OC). The BRCA1/2 and poly(ADP-ribose) polymerase (PARP) proteins are considered the foremost mediators among the various components of double-strand and single-strand repair, respectively. A series of new therapeutic drugs that target PARP have been developed for BRCAm OC. This class of agents provokes tumour-specific cytotoxicity with minimal side effects by inducing synthetic lethality, of which they are the first clinical example. The European Medicines Agency granted accelerated licensing approval for the first-in-class-drug that inhibits PARP, olaparib (Lynparza, AstraZeneca). Olaparib can be used as a monotherapeutic maintenance treatment in patients with platinum-sensitive relapsed (germline and/or somatic) BRCAm high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer responsive to platinum-based chemotherapy. Seen in light of these recent events, this review article will focus on (a) how PARP-inhibitors exploit cancer-specific defects in the homologous recombination repair apparatus and (b) how BRCA testing is implemented in routine clinical care.},
  author       = {De Jaeghere, Emiel and Vandecasteele, Katrien and Claes, Kathleen and Makar, Amin and TUMMERS, PHILIPPE and Cocquyt, Veronique and Denys, Hannelore},
  issn         = {1784-3286},
  journal      = {ACTA CLINICA BELGICA},
  keyword      = {PARP-inhibitors,Olaparib,BRCA,Ovarian cancer,Targeted therapy,RIBOSE POLYMERASE INHIBITORS,OLAPARIB MAINTENANCE THERAPY,POLY(ADP-RIBOSE) POLYMERASE,HOMOLOGOUS RECOMBINATION,SOMATIC MUTATIONS,PHASE-2 TRIAL,BRCA STATUS,REPAIR,TUMORS,CELLS},
  language     = {eng},
  number       = {1},
  pages        = {6--11},
  title        = {Incorporating PARP-inhibitors into clinical routine : a tailored treatment strategy to tackle ovarian cancer},
  url          = {http://dx.doi.org/10.1080/17843286.2016.1188455},
  volume       = {72},
  year         = {2017},
}

Chicago
De Jaeghere, Emiel, Katrien Vandecasteele, Kathleen Claes, Amin Makar, PHILIPPE TUMMERS, Veronique Cocquyt, and Hannelore Denys. 2017. “Incorporating PARP-inhibitors into Clinical Routine : a Tailored Treatment Strategy to Tackle Ovarian Cancer.” Acta Clinica Belgica 72 (1): 6–11.
APA
De Jaeghere, E., Vandecasteele, K., Claes, K., Makar, A., TUMMERS, P., Cocquyt, V., & Denys, H. (2017). Incorporating PARP-inhibitors into clinical routine : a tailored treatment strategy to tackle ovarian cancer. ACTA CLINICA BELGICA, 72(1), 6–11.
Vancouver
1.
De Jaeghere E, Vandecasteele K, Claes K, Makar A, TUMMERS P, Cocquyt V, et al. Incorporating PARP-inhibitors into clinical routine : a tailored treatment strategy to tackle ovarian cancer. ACTA CLINICA BELGICA. 2017;72(1):6–11.
MLA
De Jaeghere, Emiel, Katrien Vandecasteele, Kathleen Claes, et al. “Incorporating PARP-inhibitors into Clinical Routine : a Tailored Treatment Strategy to Tackle Ovarian Cancer.” ACTA CLINICA BELGICA 72.1 (2017): 6–11. Print.